Balancing CNS Control, Systemic Efficacy, and Quality of Life in EGFR Mutated Metastatic Non-Small Cell Lung Cancer

In this segment, the panel further examines the case of a patient with EGFR mutated metastatic non-small cell lung cancer and asymptomatic brain metastases. Dr. Rotow discusses how intracranial efficacy data from first line trials are interpreted in clinical practice, emphasizing the importance of CNS response rates, intracranial progression free survival, and durability of brain control when selecting therapy. She notes that differences in trial design and imaging schedules must be considered when evaluating CNS outcomes across studies.

Dr. Singhi then addresses the challenge of balancing systemic disease control, intracranial activity, and safety. He underscores that optimal treatment selection requires integrating survival benefit with toxicity profiles and patient specific risk factors. The discussion concludes with consideration of administration route and visit frequency, highlighting how treatment logistics influence shared decision making for patients who wish to maintain daily activities while achieving durable CNS control in EGFR mutated metastatic non-small cell lung cancer.